ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: INFO12-TH

Safety and Tolerability of Auryxia® (Ferric Citrate) in Children with Hyperphosphatemia Related to CKD

Session Information

  • Informational Posters - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • No subcategory defined


  • Ullah, Irfan, Akebia Therapeutics Inc, Cambridge, Massachusetts, United States
  • Nayak, Anjali B., Phoenix Children's Hospital, Phoenix, Arizona, United States
  • Zhang, Zhiqun, Akebia Therapeutics Inc, Cambridge, Massachusetts, United States

Ferric citrate (Auryxia®) is an oral phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis. This study aims to assess the safety and tolerability of ferric citrate in pediatric patients with hyperphosphatemia related to CKD ( Identifier: NCT04523727).

This phase 3, single-arm, open-label study will evaluate 3-times-daily oral ferric citrate for treatment of pediatric patients with hyperphosphatemia-related CKD for up to 36 weeks (Figure). Key inclusion criteria include patients 2 to <17 years of age with dialysis-dependent or non–dialysis-dependent CKD (eGFR <30 mL/min/1.73 m2), a documented history of CKD-related hyperphosphatemia for at least 3 months, serum phosphorus levels of >5.8 mg/dL for patients aged 12 years and >4.5 mg/dL for those aged 13 to <17 years, serum ferritin <500 ng/mL, and transferrin saturation <50%. The study consists of a screening period for up to 6 weeks, which includes a washout period for patients currently on phosphate binder(s), followed by a 36-week treatment period and a 30-day safety follow-up period after the last dose of study drug. Primary endpoints to assess safety and tolerability are based on incidence and severity of treatment-emergent adverse events (TEAEs), including gastrointestinal AEs of special interest, clinically significant laboratory abnormalities, and TEAEs leading to discontinuation of ferric citrate. Change from baseline in serum phosphorus to week 12/early termination will be assessed as a secondary endpoint.
This study is in progress and actively screening and enrolling patients. The results will be presented in subsequent publications.
This study will offer valuable insights into the safety and tolerability of ferric citrate in a pediatric population and advance our understanding of the benefits/risks associated with ferric citrate.

Figure. Study Design


  • Akebia Therapeutics, Inc.